PFS
PFS as the primary endpoint was statistically significantly prolonged in patients randomized to receive zolbetuximab versus placebo (median, 8.21 months versus 6.80 months, respectively; hazard ratio (HR) = 0.687; 95% confidence interval (CI), 0.544–0.866; 